FutureLife Group Strengthens Italian Presence with Acquisition of Milano Fertility Clinic

FutureLife, one of the major pan-European providers of fertility, IVF and genetics services, performing more than 77,000 IVF cycles annually and backed by CVC Capital Partners ('CVC') and Hartenberg Holding ('Hartenberg'), is proud to announce the acquisition of Milano Fertility Clinic, a fertility centre located in the heart of Milan.

Milano Fertility Clinic is a new and fast-growing fertility centre located in the vibrant heart of Milan, a city with one of the highest demands for reproductive care in Italy. Its modern infrastructure, multidisciplinary team, and patient-first approach make it a clinic with significant potential for growth and innovation. By joining FutureLife Group, Milano Fertility Clinic will benefit from the international expertise, advanced technologies, and collaborative network of one of Europe’s leading fertility providers—accelerating its development while continuing to serve local patients with excellence.

“We’re thrilled to welcome Milano Fertility Clinic into the FutureLife family. This acquisition marks a new chapter for reproductive care in Milan—combining the clinic’s enormous growth potential with the global resources and medical expertise of our group.” said Francisco Lobbosco, CEO of FutureLife Group.

“Joining FutureLife opens new pathways for our clinic and patients. We’re gaining access to a wider ecosystem of support, collaboration, and innovation that will elevate our services and accelerate growth.” said Professor Nikolaos Prapas, President of Milano Fertility Clinic.

“This partnership empowers us to achieve the vision we set out with—building a world-class fertility centre that offers patients personalised care backed by international excellence.” said Dr. Gianalfredo Franzoni, Medical Director of Milano Fertility Clinic. 

About FutureLife

FutureLife is one of the leading European providers of IVF, fertility treatments and related genetic services. With 50+ well-invested clinics, in 16 countries, employing more than 2,100 specialists performing in excess of 77,000 IVF cycles annually, as well as a series of gynaecological and surgical treatments.

In addition to its fertility clinic portfolio, FutureLife also operates hospitals in the Czech Republic and the GNT Lab, one of the largest and most modern genetic laboratories in Europe and enables the group to meet the demand for genetic services with speed and efficiency, raising the level of care provided to the group’s patients.

The team at FutureLife believe in a world where everyone has the freedom to create a family and adopt an evidence-based approach to the innovation of treatment strategies, with a mission statement focused on ethics and standards.

FutureLife is co-owned by CVC and Hartenberg. www.futurelifegroup.com

Press contacts

For FutureLife:
Jane Exon
pressoffice@futurelifegroup.com

Martin Eckstein
martin@eckstein.cz